CZ292631B6 - Deriváty pyridonkarboxylové kyseliny, protinádorové a farmakologické prostředky je obsahující - Google Patents

Deriváty pyridonkarboxylové kyseliny, protinádorové a farmakologické prostředky je obsahující Download PDF

Info

Publication number
CZ292631B6
CZ292631B6 CZ19963643A CZ364396A CZ292631B6 CZ 292631 B6 CZ292631 B6 CZ 292631B6 CZ 19963643 A CZ19963643 A CZ 19963643A CZ 364396 A CZ364396 A CZ 364396A CZ 292631 B6 CZ292631 B6 CZ 292631B6
Authority
CZ
Czechia
Prior art keywords
group
halogen
substituted
hydrogen atom
carbon atoms
Prior art date
Application number
CZ19963643A
Other languages
Czech (cs)
English (en)
Other versions
CZ364396A3 (en
Inventor
Kyoji Tomita
Katsumi Chiba
Shigeki Kashimoto
Koh-Ichiro Shibamori
Yasunori Tsuzuki
Original Assignee
Dainippon Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co., Ltd. filed Critical Dainippon Pharmaceutical Co., Ltd.
Publication of CZ364396A3 publication Critical patent/CZ364396A3/cs
Publication of CZ292631B6 publication Critical patent/CZ292631B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CZ19963643A 1994-06-14 1995-06-06 Deriváty pyridonkarboxylové kyseliny, protinádorové a farmakologické prostředky je obsahující CZ292631B6 (cs)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP15657894 1994-06-14
JP19792194 1994-07-28
JP30691494 1994-11-15
JP33995694 1994-12-28
JP8170595 1995-03-13

Publications (2)

Publication Number Publication Date
CZ364396A3 CZ364396A3 (en) 1997-06-11
CZ292631B6 true CZ292631B6 (cs) 2003-11-12

Family

ID=27524935

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ19963643A CZ292631B6 (cs) 1994-06-14 1995-06-06 Deriváty pyridonkarboxylové kyseliny, protinádorové a farmakologické prostředky je obsahující

Country Status (27)

Country Link
US (1) US5817669A (enExample)
EP (1) EP0787726B1 (enExample)
JP (1) JP3391796B2 (enExample)
KR (1) KR100350921B1 (enExample)
CN (1) CN1053668C (enExample)
AT (1) ATE209645T1 (enExample)
AU (1) AU679859B2 (enExample)
BR (1) BR9508037A (enExample)
CA (1) CA2192824C (enExample)
CZ (1) CZ292631B6 (enExample)
DE (1) DE69524251T2 (enExample)
DK (1) DK0787726T3 (enExample)
ES (1) ES2163512T3 (enExample)
FI (1) FI112485B (enExample)
HK (1) HK1000495A1 (enExample)
HU (1) HU220072B (enExample)
MX (1) MX9606331A (enExample)
NO (1) NO307255B1 (enExample)
NZ (1) NZ287139A (enExample)
PL (1) PL181867B1 (enExample)
PT (1) PT787726E (enExample)
RO (1) RO117793B1 (enExample)
RU (1) RU2151770C1 (enExample)
SI (1) SI0787726T1 (enExample)
SK (1) SK281341B6 (enExample)
TW (1) TW319769B (enExample)
WO (1) WO1995034559A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040041178A (ko) 2001-09-26 2004-05-14 바이엘 파마슈티칼스 코포레이션 당뇨병 치료제로서 1,8-나프티리딘 유도체
US6802423B2 (en) * 2002-02-20 2004-10-12 Trans Global Foods, Inc. Disposable food delivery apparatus
WO2004091627A2 (en) * 2003-04-07 2004-10-28 Cylene Pharmaceuticals, Inc. Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
ES2424676T3 (es) * 2003-09-10 2013-10-07 Kyorin Pharmaceutical Co., Ltd. Derivado de ácido 7-(3-ciclopropilaminometil-1-pirrolidinil 4-sustituido)quinoloncarboxílico
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
AU2013201203C1 (en) * 2004-03-15 2015-04-23 Sumitomo Dainippon Pharma Co., Ltd. Sns-595 and methods of using the same
DK2295056T5 (en) 2004-03-15 2016-11-28 Sunesis Pharmaceuticals Inc Use of SNS-595 to treat leukemia
JP2008516905A (ja) * 2004-10-14 2008-05-22 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄｋ１抗増殖活性を有する１，５−ナフチリジンアゾリジノン
CN101039939B (zh) * 2004-10-14 2010-07-07 霍夫曼-拉罗奇有限公司 作为cdk1抑制剂的喹唑啉基亚甲基噻唑啉酮类
US7563805B2 (en) 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative
RU2420524C2 (ru) * 2005-05-19 2011-06-10 Дайити Санкио Компани, Лимитед Производные три- или тетра-замещенного-3-аминопирролидина
JP2009504192A (ja) * 2005-08-19 2009-02-05 サイリーン ファーマシューティカルズ インコーポレーティッド ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用
JP5374153B2 (ja) * 2005-09-02 2013-12-25 サネシス ファーマシューティカルズ， インコーポレイテッド 癌の治療のための（＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸を使用する方法
AU2013219242C1 (en) * 2005-09-02 2016-09-22 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
EP1931339B1 (en) * 2005-09-02 2018-05-16 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
RU2428983C2 (ru) * 2005-09-02 2011-09-20 Санесис Фармасьютикалз, Инк. Способы применения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты для лечения рака
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CN104873502A (zh) * 2005-09-02 2015-09-02 逊尼希思制药公司 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
AU2006291007A1 (en) * 2005-09-14 2007-03-22 Janssen Pharmaceutica, N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
KR20090021215A (ko) 2006-06-12 2009-02-27 선에시스 파마슈티컬스 인코포레이티드 암의 치료를 위한 화합물 및 조성물
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DK2049109T3 (en) 2006-08-02 2016-01-11 Sunesis Pharmaceuticals Inc Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
EP3141250A1 (en) * 2007-10-22 2017-03-15 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
WO2009075841A2 (en) * 2007-12-10 2009-06-18 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
KR20170090535A (ko) * 2008-12-31 2017-08-07 선에시스 파마슈티컬스 인코포레이티드 (＋)-1,4-다이하이드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리딘일］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법
CA2753261A1 (en) 2009-02-27 2010-09-02 Sunesis Pharmaceuticals, Inc. Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
MX347952B (es) 2011-05-13 2017-05-19 Array Biopharma Inc Compuestos de pirrolidinil urea y pirrolidinil tiourea como inhibidores de cinasa trka.
CN103497186B (zh) * 2013-09-24 2015-02-25 浙江司太立制药股份有限公司 含有烷氧亚氨基取代的萘啶酮羧酸衍生物及其制备方法
CN110520422B (zh) * 2017-03-24 2023-09-05 涌永制药株式会社 新型吡啶酮羧酸衍生物或其盐

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988463A (en) * 1974-05-06 1976-10-26 Merck & Co., Inc. Method of preventing metastasis of H. Ep. No. 3
US4384001A (en) * 1978-12-21 1983-05-17 Gosalvez Mario Treatment of tumors with thiazolidine-4-carboxylic acid
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
NZ210847A (en) * 1984-01-26 1988-02-29 Abbott Lab Naphthyridine and pyridopyrimidine derivatives and pharmaceutical compositions
DE3577089D1 (de) * 1984-01-26 1990-05-17 Abbott Lab Antibakterielle chinolinderivate.
JPS61152682A (ja) * 1984-12-27 1986-07-11 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体、そのエステルおよびその塩
JPS61251667A (ja) * 1985-04-30 1986-11-08 Otsuka Pharmaceut Co Ltd ベンゾヘテロ環化合物
IE60420B1 (en) * 1985-06-13 1994-07-13 Schering Corp Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
EP0226624A1 (en) * 1985-06-14 1987-07-01 The Upjohn Company Cyclopentapyrazole and tetrahydroindazole compounds
JPS6233176A (ja) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
JP2704428B2 (ja) * 1988-06-15 1998-01-26 富山化学工業株式会社 キノロンカルボン酸誘導体またはその塩
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JPH06233176A (ja) * 1993-01-29 1994-08-19 Sony Corp ビデオカメラ

Also Published As

Publication number Publication date
JP3391796B2 (ja) 2003-03-31
DE69524251D1 (de) 2002-01-10
AU2576795A (en) 1996-01-05
CA2192824C (en) 2006-11-07
CA2192824A1 (en) 1995-12-21
HUT75777A (en) 1997-05-28
BR9508037A (pt) 1997-09-16
PT787726E (pt) 2002-04-29
MX9606331A (es) 1997-03-29
SK157496A3 (en) 1997-08-06
EP0787726B1 (en) 2001-11-28
FI965020A0 (fi) 1996-12-13
ES2163512T3 (es) 2002-02-01
FI112485B (fi) 2003-12-15
PL317726A1 (en) 1997-04-28
RU2151770C1 (ru) 2000-06-27
AU679859B2 (en) 1997-07-10
CN1158614A (zh) 1997-09-03
PL181867B1 (pl) 2001-09-28
HU220072B (hu) 2001-10-28
NO965305L (no) 1997-02-04
EP0787726A4 (enExample) 1997-08-06
NO307255B1 (no) 2000-03-06
SI0787726T1 (en) 2002-04-30
CZ364396A3 (en) 1997-06-11
TW319769B (enExample) 1997-11-11
DE69524251T2 (de) 2002-07-11
NZ287139A (en) 1997-07-27
HU9603455D0 (en) 1997-02-28
NO965305D0 (no) 1996-12-11
WO1995034559A1 (en) 1995-12-21
HK1000495A1 (en) 2002-07-19
DK0787726T3 (da) 2002-02-11
FI965020A7 (fi) 1996-12-16
ATE209645T1 (de) 2001-12-15
CN1053668C (zh) 2000-06-21
US5817669A (en) 1998-10-06
KR100350921B1 (ko) 2002-11-18
SK281341B6 (sk) 2001-02-12
EP0787726A1 (en) 1997-08-06
RO117793B1 (ro) 2002-07-30

Similar Documents

Publication Publication Date Title
CZ292631B6 (cs) Deriváty pyridonkarboxylové kyseliny, protinádorové a farmakologické prostředky je obsahující
JPWO1995034559A1 (ja) 新規化合物、その製法および抗腫瘍剤
TWI894413B (zh) 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法
HK1000495B (en) Novel compound, process for producing the same, and antitumor agent
JP4323574B2 (ja) 抗腫瘍剤
CN104854101B (zh) Alk激酶抑制剂
JP3514490B2 (ja) トリフルオロメチルピロロインドールカルボン酸エステル誘導体及びその製造方法
US6316438B1 (en) Fused pyridopyridazine inhibitors of cGMP phosphodiesterase
TW200813020A (en) Substituted 3-amino-pyrrolidino-4-lactams
HU194561B (en) Process for preparing novel, aminopyrrolidinyl group-substituted 1,8-naphthyridine derivatives and pharmaceuticals comprising such compounds as active substance
IE63492B1 (en) A Spiro Compound
KR20160034384A (ko) 인돌 및 피롤의 유도체, 이의 제조 방법 및 이를 함유하는 약제 조성물
CN1312131C (zh) 包含作为活性成分的吡啶酮羧酸的抗耐酸细菌药
JP2948660B2 (ja) 新規なピリドンカルボン酸誘導体
EP4660193A1 (en) Indole compound decomposing ikzf2, and use thereof
HUT61304A (en) Process for producing azetidinyl-substituted pyridone derivatives and pharmaceutical compositions comprising such compounds
JP5079612B2 (ja) 抗腫瘍剤
WO1995021163A1 (en) Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor
CN108948003B (zh) 作为mTOR抑制剂的吡嗪并[2,3-c]喹啉-2（1H）-酮类化合物的制备及用途
JPH0873460A (ja) １，８−ナフチリジン化合物および抗腫瘍剤
KR100332527B1 (ko) 피리돈카르본산유도체또는이것의염및그제조방법
TW202233601A (zh) 新穎雜環化合物
WO1997031919A1 (en) Pyridonecarboxylic acid derivatives and intermediates for the synthesis thereof
JPH0834786A (ja) トリフルオロメチルピロロインドール誘導体及びその製造方法
JPH0834787A (ja) ピロロカルバゾール誘導体及びその製造方法

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MK4A Patent expired

Effective date: 20150606